Orthogonal platform enhances protein separation and characterisation
Enables labs around the world to generate more useful information from complex proteins, antibodies, polypeptides and polysaccharides.
Postnova Analytics reports on the extended data available through integrating its AF2000 MultiFlow Flow Field-Flow Fractionation (FFF) platform with its SC2000 modular multi-detector Size Exclusion chromatography (SEC) system.
Drawing on over three decades of cutting-edge separations leadership, Postnova has designed an advanced orthogonal system that allows both SEC and FFF separations to be carried out on the same sample within one instrument platform. The result is enabling labs around the world to generate more useful information from even complex proteins, antibodies, polypeptides and polysaccharides.
As both separation techniques in the Postnova 2000 Series FFF/SEC system can use the same optimised detector set - UV, RI and MALS (Multi Angle Light Scattering) realising the enhanced applications potential of the integrated system is achieved with minimal redundancy using an automatic switching value and software upgrade kit.
Offering orthogonally operating separation techniques in same platform, the Postnova 2000 Series FFF/SEC system delivers unmatched diagnostic flexibility across an increased application range. The system can be run with different eluents, pH and wide-ranging temperature conditions making it an ideal platform for the characterization of natural or synthetic macromolecules.
Postnova FFF technology employs a unique crossflow field in which samples are separated by their dynamic diffusion based on molar mass or particle size. Because of this design and the absence of any stationary phase, separations are performed without exerting shear forces and stress on the molecules.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.